Keyword: AstraZeneca

AZ continued its rights-sale strategy through a $42 million deal on Seroquel and Seroquel XR with Cheplapharm.

With the priority review, Imfinzi is now looking at a decision for use in frontline small cell lung cancer by the first quarter of 2020.

It’s a familiar scene in the race onto China’s national reimbursement list: Drugmakers cut prices by an average 60.7% to win coverage.

AstraZeneca is hitting the road to ramp up its education and awareness around the link between Type 2 diabetes and heart failure.

Imbruvica has enjoyed a nice run in previously untreated CLL over the last few years. But major competition is here in the form of AZ's Calquence.

Keytruda's U.S. NSCLC sales might start to fall as soon as early 2020, one analyst says, as I-O rivals eat into its share based on recent successes.

Despite having lost some of its novelty, AZ's Brilinta is touting bleeding data over aspirin that could be a big break in acute coronary syndrome.

AstraZeneca's Farxiga is touting its heart failure data in patients with or without diabetes, but results in non-diabetics look particularly strong.

To show Brukinsa is better than AbbVie and J&J's blockbuster Imbruvica, BeiGene is running phase 3 head-to-head trials in blood cancers.

A look at third-quarter numbers shows many top players are rolling right along—though some Big Pharmas weren't so lucky.